Background: Several lines of evidence have suggested a relationship between a woman's number of ovulatory cycles and the development of ovarian epithelial cancer. Repair of the ovarian surface after ovulation requires cellular proliferation, and spontaneous mutations arising during the DNA synthesis that accompanies this proliferation may play a role in carcinogenesis. Purpose: We conducted a molecular epidemiologic study to test the hypothesis that a greater number of ovulatory cycles increases the risk of ovarian cancer by inducing proliferation-associated DNA damage. In particular, we examined the association between the lifetime number of ovulatory cycles and mutation of the p53 tumorsuppressor gene (also known as TP53) in ovarian tumors. 
Background: Several lines of evidence have suggested a relationship between a woman's number of ovulatory cycles and the development of ovarian epithelial cancer. Repair of the ovarian surface after ovulation requires cellular proliferation, and spontaneous mutations arising during the DNA synthesis that accompanies this proliferation may play a role in carcinogenesis. Purpose: We conducted a molecular epidemiologic study to test the hypothesis that a greater number of ovulatory cycles increases the risk of ovarian cancer by inducing proliferation-associated DNA damage. In particular, we examined the association between the lifetime number of ovulatory cycles and mutation of the p53 tumorsuppressor gene (also known as TP53) in ovarian tumors. Several lines of evidence suggest that incessant ovulation plays a role in the development of epithelial ovarian cancer in women. First, epithelial ovarian cancer is exceedingly rare in anovulatory women with gonadal dysgenesis. In addition, although epithelial ovarian cancer rarely occurs in most other animal species, it is common in hens, which, like humans, are frequent ovulators (1) . Finally, epidemiologic studies have shown that pregnancy, breast-feeding, and oral contraceptive use, which inhibit ovulation, are protective against the development of ovarian cancer (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) .
Although the relationship between incessant ovulation and ovarian cancer is well accepted, the underlying causative mechanisms remain unclear. Several hypotheses, all or none of which may be correct, have been advanced to explain this association. It has been suggested that exposure to high levels of gonadotropins and steroid hormones at ovulation may facilitate transformation (12) . In addition, ovulation leads to entrapment of epithelial cells in the underlying stroma, with subsequent formation of inclusion cysts. These cysts could represent precursor lesions in which transformation is facilitated. Finally, proliferation of epithelial cells required to repair the disrupted ovarian surface after ovulation could contribute to carcinogenesis by increasing the likelihood of mutations due to spontaneous errors in DNA synthesis (13, 14) . If mutations involve critical growth regulatory genes, this could facilitate clonal expansion of premalignant cells with an increased susceptibility to subsequently become fully transformed.
Because of the inaccessibility of the ovaries and the absence of an obvious premalignant precursor lesion in the ovarian epithelium, it has been difficult to define a sequence of molecular events involved in malignant transformation in the ovary as has been possible in squamous or colonic epithelium. Mutation and overexpression of the p53 tumor-suppressor gene (also known as TP53) are the most frequently observed molecular alterations in ovarian cancers, as is the case in many other types of cancers, and occur in approximately 50% of the cases (15) (16) (17) (18) .
Our group and others have shown that a majority of the p53 mutations in ovarian cancers are transitions. It has been hypothesized that this observed spectrum of mutations is indirect evidence that these mutations arise due to spontaneous errors in DNA synthesis associated with proliferation (19) . Since proliferation of ovarian epithelium is thought to occur primarily following ovulation, it would be predicted that a relationship should exist between lifetime ovulatory cycles and mutation of the p53 gene in ovarian cancers. Since not all ovarian tumors exhibit a mutation in p53, we hypothesize that p53 mutation status may be indicative of a distinct etiologic subgroup of these tumors.
Identification of etiologic subgroups of ovarian cancer on the molecular level may be useful in the clarification of risk factors associated with the risk of this disease. To test this hypothesis, paraffin blocks were obtained from ovarian cancer cases accessioned in conjunction with the Cancer and Steroid Hormone (CASH) study, a large population-based, case-control study. Immunostaining was performed to detect overexpression of mutant p53 protein, and the relationship to lifetime ovulations and other risk factors was examined using case-case and case-control analyses.
Methods

Study Population
Subjects in the current study are a subset of patients with epithelial ovarian cancer and control subjects participating in the CASH study. Case patients in the original study were identified from eight population-based tumor registries of the Surveillance, Epidemiology, and End Results (SEER) 1 Program. Details of the CASH study have been described previously (2) . Case patients in this current study include women aged 20-54 years with histologically confirmed epithelial ovarian cancer that was diagnosed from December 1, 1980, through December 31, 1982, selected from the five largest SEER registries in the CASH study, which include Atlanta, GA; Detroit, MI; San Francisco, CA; Connecticut; and Iowa. Because of the possibility of etiologic and molecular differences in invasive and borderline ovarian tumors (20, 21) , the current study was restricted to invasive cases. There were 316 women with invasive epithelial ovarian cancer registered in the five SEER sites included in this study.
Control subjects were 3363 women who resided in the same five geographic locations as the case patients and were ascertained through random-digit dialing. All control subjects were 20-54 years of age and restricted to those women at risk for a first primary ovarian cancer at the time of the interview. Women who had both ovaries removed prior to the interview, who had a prior history of ovarian cancer, or who were unable to provide information as to whether they had ovaries were excluded.
Data Collection and Analysis Variables
A questionnaire was administered in the home of each study participant. The questionnaire included items concerning socioeconomic information, age at menarche and at menopause, use of oral contraceptives and other hormones, infertility (defined as no conception after 2 years of trying to conceive that was diagnosed by a physician to be a problem in the woman or both the woman and the partner), pregnancy, breast-feeding, medical history, and family history of cancer. Relative weight for height was quantified by the Quetelet's index (kg/m 2 ) for current weight. The main exposure variable, number of lifetime ovulatory cycles (LOC), was calculated based on the following formula:
LOC ‫ס‬ (index age − age at first menstrual period*13) − [(number of months of breast-feeding + number of months pregnant + number of months of oral contraceptive use)*13/12], where a cycle length of 28 days is assumed, or an average of 13 cycles per year. Index age is defined as age at last menstrual period. If the respondent had a hysterectomy, without an oophorectomy, index age is the current age for those less than 49 years or 49 years for those older than 49.
An ordinal variable for LOCs was created to reflect low, medium, or high exposure to ovulation. Cutoff points for this LOC variable were based on estimates of the expected number of ovulatory cycles that a woman would have by a certain age, considering an average of 13 cycles per year after menarche. The average age of menarche was found to be approximately 12 years (standard deviation [SD] ‫ס‬ 1.5) in this population. When subjects were stratified according to p53 status or case-control status, the average age at menarche remained the same. Therefore, an age of 12 years at menarche was applied to the derivation of the cut-points. Thus, the categories of ovulatory cycles relate to an approximate age range. For women aged 30 years or younger, the expected number of ovulatory cycles was 234 or less (low exposure), from 30 to 40 years was 235-375 cycles (medium exposure), and 40 years or older was 376-533 cycles (high exposure).
Tissue Specimen Retrieval
Identifying variables for the ovarian cancer cases, including the SEER accession number, the CASH study identification No., date of birth, and date at diagnosis, were provided to the respective SEER registries. This information was merged with the registry's database to locate tissue specimens for each of the case patients. Paraffin-embedded tissue blocks and pathology reports were requested from the diagnosing institutions of each case patient by the respective registries.
Tumor Characteristics and Pathologic Review
An expert panel of three pathologists reviewed histologic material from patients with epithelial ovarian cancer. Information on the histologic subtype, tumor behavior (invasive versus borderline), and tumor grade were available through pathologic review by study pathologists. A computer file containing the stage at diagnosis (local, regional, or distant) was obtained from the respective SEER registries and merged with the CASH database.
Laboratory Analysis
Immunostaining for p53 was performed by the Duke Comprehensive Cancer Center Immunohistochemistry Facility as previously described (22) . Slides containing 4-to 6-m-thick sections of ovarian cancers were heated to 65°C for 60 minutes and then deparaffinized in three changes of xylene followed by three rinses of absolute ethanol. Slides were hydrated in ethanol, rinsed in phosphatebuffered saline (PBS), and incubated in 5% normal horse serum followed by an incubation for 45 minutes with primary antibody. Monoclonal antibody PAb 1801 (1 g/mL) (Oncogene Science, Inc., Cambridge, MA), which recognizes an epitope located between amino acids 32 and 79 (23) , was used to detect p53. Mouse immunoglobulin G1 (IgG1) (1 g/mL) was used as a control to assess nonspecific staining. Slides were rinsed with PBS and incubated with the secondary antibody for 20 minutes (biotinylated, affinity-purified horse anti-mouse IgG). Slides were rinsed in PBS followed by 20 minutes of incubation in premixed Elite Universal Kit (Vector Laboratories, Inc., Burlingame, CA) reagents. Slides were then rinsed again with PBS and sections were developed with the enzyme substrate diaminobenzidine. The slides were scored for p53 immunostaining without the knowledge of the clinical or epidemiologic data. p53 immunostaining was scored as positive only if definite nuclear staining was present in a significant (>10%) fraction of malignant cells. It has been shown that 90% of the case patients have p53 mutations when a cutoff point of more than 10% is applied to staining in paraffin blocks (22) .
Statistical Analysis
Mantel-Haenszel chi-squared tests for ordered outcomes, Pearson chi-squared tests for nonordered outcomes, and t tests were used to test bivariate associations between factors related to p53 and case-control status. Associations were quantified by the use of odds ratios (ORs) and 95% confidence intervals (CIs) for crude estimates of the case-case analysis of the association between the p53-positive versus the p53-negative case patients as well as case-control comparisons between each of the two case patient groups. Potential confounders, possible risk factors for ovarian cancer, were first evaluated by determining whether the point estimate for the association between LOC and p53 status or casecontrol status varied by more than 10% from the age-adjusted OR when included one at a time in a logistic regression equation. All variables found to be associated with a greater than 10% change in the age-adjusted OR for LOC and the respective outcome, either p53 status or case-control status, were included in the final models. Multivariate analyses, with the use of the logistic regression, were conducted to estimate the OR for both the case-case and case-control analyses while simultaneously controlling for other covariates. A significance level of P ‫ס‬ .05 was applied. Two-sided statistical tests were used to evaluate the data.
Results
Representativeness of Study Sample
Of the 316 eligible patients with ovarian cancer, 197 subjects (62.3%) were available for the current study and had specimens analyzed for the presence of p53 overexpression. Differences in tumor retrieval were observed according to the SEER center, ranging from 35% (Atlanta) to 82% (Iowa). To assess possible selection bias, we compared the personal and tumor characteristics of the case patients for whom p53 results were available with those without p53 results ( Table 1) . None of the personal characteristics examined were found to be statistically different among ovarian cancer case patients with a completed p53 analysis compared with those for whom p53 results were not available. The distributions of several important risk factors, including oral contraceptive use, months pregnant, and LOC, were not significantly different among case patients for whom p53 results were available versus case patients without p53 results. In addition, no differences in the availability of a p53 analysis were found according to tumor characteristics.
Case-Case Analyses
The results of the immunohistochemical analysis revealed that 105 case patients (53%) were positive for p53 overexpression (p53 positive) and 92 case patients (47%) did not overexpress p53. Descriptive statistics of the personal and pathologic characteristics of the case patients with p53-positive ovarian cancer and p53-negative ovarian cancer are found in Table 2 . Crude ORs illustrate that p53-positive case patients were exposed to significantly more ovulatory cycles, were older at diagnosis, were less likely to be premenopausal, and were more likely to report a family history of breast cancer in a first-degree relative compared with the p53-negative case patients. In addition, we found a statistically significant difference in the mean number of ovulatory cycles according to p53 status, with p53-positive case patients having a mean of 388 (SD ‫ס‬ 77.4) lifetime ovulatory cycles compared with a mean of 342 (SD ‫ס‬ 119.0) lifetime ovulatory cycles among the p53-negative case patients (P ‫ס‬ .0025). None of the patients with ovarian cancer in the current study reported a family history of ovarian cancer.
Differences were found in the pathologic characteristics of p53-positive case patients compared with p53-negative case patients. Overexpression of p53 was found to be associated with moderate to poor grade and distant stage at diagnosis. Tumors that overexpressed p53 were more likely to be classified as serous and less likely to be classified as mucinous compared with tumors that did not overexpress p53 protein.
ORs and 95% CIs for the age-adjusted and multivariate analyses of p53-positive case patients versus p53-negative case patients are found in Table 3 . Age-adjusted ORs for the association between LOC exposure and p53 status were 7.0 (95% CI ‫ס‬ 1.6-30.5) and 7.7 (95% CI ‫ס‬ 1.4-41.2) for exposure to medium LOC (235-375 cycles) and high LOC (376-533 cycles), respectively. Of note, only four of the p53-positive case patients were classified as having a low level of ovulatory cycle exposure compared with 23 p53-negative case patients.
Variables in Table 2 , excluding those used to determine LOC exposure, were evaluated as potential confounders as described in the ''Methods'' section. All factors determined to have an effect on the association between LOC exposure and p53 status were included in a logistic regression equation. Although there was evidence for confounding by age at diagnosis (see age- adjusted ORs in Table 3 compared with crude estimates in Table  2 ), there was little evidence for confounding when menopausal status, family history of breast cancer, tumor grade, and tumor stage were included in the multivariate analysis. The multivariate adjusted ORs were 7.7 (95% CI ‫ס‬ 1.6-37.8) and 7.8 (95% CI ‫ס‬ 1.3-47.6) for medium and high LOC exposure, respectively. In these analyses, both the main effect for age (at diagnosis) and the age 2 term were entered into the model because the linear term for age alone did not represent adequately the description of age in these data.
To determine whether the effects of anovulation due to months of oral contraceptive use, months of pregnancy, and months of breast-feeding were similar in magnitude, continuous variables for these effects were entered into a logistic regression equation, controlling for age and age at menarche. Comparison of the slopes of these variables demonstrated that they were not statistically significantly different from each other.
Case-Control Analyses
Bivariate analyses in Table 2 revealed that several factors were significantly associated with case-control status for both p53-positive and -negative case patients, including months of breast-feeding, months pregnant, and months of oral contraceptive use. Age at diagnosis, race, education, family history of breast cancer, and menopausal status were significantly associated with the risk of p53-positive ovarian cancer but not p53-negative ovarian cancer in the case-control comparisons.
As shown in Table 3 , both the age-adjusted and multivariate analyses revealed a statistically significant, dose-response relationship between increasing LOC exposure and the risk of developing p53-positive ovarian cancer. Controlling for age, menopausal status, and nulliparity in the multivariate analysis, adjusted ORs for p53-positive case patients versus control subjects were found to be 4.3 (95% CI ‫ס‬ 1.4-13.0) and 9.1 (95% CI ‫ס‬ 2.7-30.9) for exposure to moderate and high levels of ovulatory cycles, respectively. In contrast, no association between LOC exposure and p53-negative ovarian cancer case patients versus control subjects was found with OR ratios of 0.6 (95% CI ‫ס‬ 0.3-1.4) and 1.3 (95% CI ‫ס‬ 0.5-3.2) for medium LOC exposure and heavy LOC exposure, respectively. We compared the slopes of the continuous variables for months of oral contraceptive use, months of pregnancy, and months of breast-feeding and found no statistically significant differences for either casecontrol comparison.
Discussion
It has been suggested that many human cancers may arise as a result of the accumulation of genetic mutations that occur during DNA replication associated with normal cellular proliferation (23) . In sporadic ovarian cancers, mutation of the p53 tumor-suppressor gene occurs in approximately 50% of ovarian cancers, including 50% of stage III or IV (17) and 15% of stage I or II (24) cases and is the most frequent molecular alteration in these cancers (15) (16) (17) . In addition to the association with advanced stage, alteration of p53 has been shown to be associated with poor histologic grade (24) and poor survival (25) . The majority of these mutations are transitions (19) , which is consistent with the hypothesis that they represent spontaneous errors in DNA replication rather than carcinogen-induced mutations (13, 26, 27) . Since proliferation of ovarian epithelium occurs primarily to repair ovulatory defects, we tested the hypothesis that high exposure to ovulation is associated with ovarian cancer characterized by overexpression of mutant p53. The present molecular epidemiologic study employing case patients and control subjects from the CASH study demonstrated a striking association between number of lifetime ovulatory cycles and overexpression of mutant p53 protein in ovarian cancers. Although the case-case comparisons aid in establishing that there is a difference in exposure to ovulation among case patients with ovarian cancer who overexpress p53 compared with those who do not, the case-control comparisons suggest that there are etiologic differences according to the p53 status of the tumor. Specifically, the case-control analyses demonstrate that ovulation may be related to an increased risk of developing p53-positive but not p53-negative ovarian cancers. These findings are also supportive of the hypothesis that mutations in the p53 tumor-suppressor gene in ovarian cancers may arise due to spontaneous errors in DNA synthesis that occur during ovulation-induced proliferation. Epithelial ovarian cancer is a heterogeneous disease in most respects, including molecular alterations (28) as well as histopathologic features, growth rate, metastatic potential, chemosensitivity, and prognosis. It is possible that clinical heterogeneity exists because ovarian cancers may arise by way of several distinct molecular pathways that are determined by the specific underlying etiologic causes. The association between high exposure to ovulation and ovarian cancer characterized by overexpression of mutant p53 supports the validity of this hypothesis.
Limitations of this study include the possibility of misclassification error. Because of the absence of information on fertility drugs and cycle length, the possibility of measurement error in the LOC exposure variable exists. We expect that misclassification of ovulatory cycle exposure is nondifferential according to the status of p53 overexpression in the tumor. It has been shown that immunostaining has a sensitivity and specificity of approximately 90% for detecting missense mutations in exons 5-9 of the p53 gene in breast and ovarian cancers (22) . In addition, 10%-20% of p53 mutations may occur outside exons 5-9, and these mutations generally do not lead to overaccumulation of p53 protein (29) . Thus, misclassification of p53 status may have occurred. However, misclassification of p53 would not be expected to be influenced by the exposure variable. Because of the different manner in which these variables were measured, it is also unlikely that the misclassification errors of p53 status and ovulation are associated. Therefore, misclassification bias in the case-case analyses is likely to be nondifferential, resulting in an attenuation of the ORs. The direction of the bias due to misclassification error in the case-control analyses is somewhat harder to anticipate. Because of the consistency between the results for the case-case and case-control analyses, we believe that misclassification error was most likely nondifferential according to case-control status.
This study is also limited in generalizability, since the subjects in this study, who were diagnosed with ovarian cancer between the ages of 20 and 54 years, do not represent the majority of ovarian cancer patients, who have an average age at diagnosis of approximately 59 years (30) . It is certainly possible that later onset ovarian cancer may be etiologically distinct from ovarian cancer with an earlier onset. Ovulation may be more important in the etiology of premenopausal ovarian cancer, whereas a different etiologic pathway may be related to later onset, postmenopausal ovarian cancer where exposure to ovulation occurred in the remote past. Further investigation is warranted to determine whether later onset ovarian cancer is etiologically distinct from ovarian cancer in younger women.
Although age at menarche and menopause, pregnancy, oral contraceptive use, breast-feeding, and infertility all affect lifetime exposure to ovulation, these risk factors also have diverse effects on gonadotropin and steroid hormone levels. In view of evidence that hormonal and dietary factors alter ovarian cancer risk (31) (32) (33) , associations between these etiologic factors and specific molecular alterations also should be explored in the future. In addition to examining p53 genes for the presence of mutations, the role of other genetic alterations, such as gene amplification and aneuploidy, should be evaluated. In many case patients, multiple etiologic and molecular features may contribute to the development of ovarian cancer. Since there were not definitive differences in the magnitude of effect of cycles averted because of pregnancy versus oral contraceptive use versus lactation, it seems unlikely that any of these three factors has a substantial effect on risk that is not mediated through their effects on ovulation.
Our results provide evidence for the existence of more than one causal pathway in the pathogenesis of ovarian cancer. It is possible that high lifetime exposure to ovulation is associated with ovarian cancer characterized by overexpression of mutant p53. Since the type of p53 mutations associated with p53 overexpression appears to be due to spontaneous errors in DNA synthesis, this further supports the hypothesis that these mutations may be due to proliferation of ovarian epithelium following ovulation.
